The CLL12 trial protocol: A placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

Future Oncology

Volumn 11, Issue 13, 2015, Pages 1895-1903

  Langerbeins, Petra ^a   Bahlo, Jasmin ^a   Rhein, Christina ^a   Cramer, Paula ^a   Pflug, Natali ^a   Fischer, Kirsten ^a   Stilgenbauer, Stephan ^b   Kreuzer, Karl Anton ^a   Wendtner, Clemens Martin ^c   Eichhorst, Barbara ^a   Hallek, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c Clinic Schwabing   (Germany)

Author keywords

B cell receptor signaling; Binet A; Bruton's tyrosine kinase; CLL; ibrutinib; wait; watch

Indexed keywords

IBRUTINIB; PLACEBO; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ADULT; ADVERSE DRUG REACTION; AGED; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRAZOLES; PYRIMIDINES; RISK;

EID: 84936938545     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.95     Document Type: Article

References (15)

1. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975-2009. National Cancer Institute, (2011). http://seer.cancer.gov/crs/1975-2012
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 352(8), 804-815 (2005).
3. Gribben JG, O'brien S. Update on therapy of chronic lymphocytic leukemia. J. Clin. Oncol. 29(5), 544-550 (2011).
4. Binet JL, Lepoprier M, Dighiero G et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 40(2), 855-864 (1977).
5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 46(2), 219-234 (1975).
6. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008).
7. Schweighofer C, Cymbalista F, Müller C et al. Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk binet stage a chronic lymphocytic leukemia-first results of a randomized German-French cooperative Phase III trial. Presented at: 55th ASH Annual Meeting and Exposition. New Orleans, LA, USA, 7-10 December 2013.
8. Pflug N, Bahlo J, Shanafelt TD et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124(1), 49-62 (2014).
9. Stilgenbauer S, Schnaiter A, Paschka P et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123(21), 3247-3254 (2014).
10. Krober A, Seiler T, Benner A et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100(4), 1410-1416 (2002).
11. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000).
12. Byrd JC, Brown JR, O'brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371(3), 213-223 (2014).
13. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32-42 (2013).
14. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008).
15. Hallek M, Cheson B, Catovsky D et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood e-letter(4 June 2012). http://dx.doi.orgfuture